Introduction: VEGF A has an important role in the vascular developmental process. VEGF A level increase in breast cancer and associated with higher rate of recurrence and mortality.
Methods: It is an observational cross-sectional study. The VEGF A levels are measured using ELISA.
Results: There is a significant difference between the size of tumor before and after administration of Neoadjuvant TAC chemotherapy: 29 (72.5%) responsive: 11 (27.5%) unresponsive, P= 0,000 (P value 0,05) which means that there is no significant difference between VEGF A before and after chemotherapy. There is an association between VEGF A level and clinical response of neoadjuvant TAC chemotherapy P = 0,037 (P value < 0,05).
Conclusion: There is a significant positive outcome in clinical response of breast cancer patients on neoadjuvant TAC chemotherapy. Decrease level of VEGF A is lower after TAC chemotherapy but not statistically significant. There is an association between VEGF A level with clinical response after neoadjuvant TAC chemotherapy in breast cancer patients.
Key words: VEGF A, breast cancer, neoadjuvant TAC chemotherapy
|
